Propranolol for infantile hemangiomas

Propranolol for infantile hemangiomas - Propranolol for infantile hemangiomas

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011944

Enrollment

Registered

2013-10-03

Start date

2013-10-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infantile hemangiomas

Interventions

The patients will start propranolol medication at the dose of 1mg/kg per day. After 1-2 weeks the dose of propranolol will increase at 2mg/kg/per day. The patients will follow at the outpatient clin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who have the disability due to hemangiomas

Exclusion criteria

Exclusion criteria: Patients who have the contraindication of propranolol

Design outcomes

Primary

Measure	Time frame
Volume of hemangioma(measured by MRI, CT and photograph)	—

Secondary

Measure	Time frame
Side effect	—

Countries

Japan

Contacts

Public ContactNoriko Aramaki

Keio university, School of medicine Plastic and Reconstructive Surgery

nonken@2001.jukuin.keio.ac.jp03-3353-1211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026